翻訳と辞書 |
Velaglucerase alfa : ウィキペディア英語版 | Velaglucerase alfa
Velaglucerase alfa (trade name VPRIV), manufactured by Shire plc is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1. It has an identical amino acid sequence to the naturally occurring enzyme.〔University of Birmingham: (Velaglucerase alfa for type 1 Gaucher’s disease )〕 It was approved for use by the U.S. Food and Drug Administration (FDA) on February 26, 2010.〔Medical News Today: (Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease ), 27 February 2010〕 ==Competitive products== Imiglucerase is Genzyme's version of recombinant glucocerebrosidase. It is marketed globally under the trade name of Cerezyme. In addition, Protalix and Pfizer are working to bring taliglucerase alpha to market in the U.S. The FDA is due to rule on its approvability in February 2011. The companies are expected also to file for marketing authorization in Europe and around the world.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Velaglucerase alfa」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|